09/29/23 7:30 AMNasdaq : OCGN conferencesOcugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders ConferenceOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s ChiefRHEA-AIneutral
09/27/23 7:30 PMNasdaq : OCGN conferencesOcugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines ConferenceOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, ChiefRHEA-AIneutral
09/21/23 7:30 AMNasdaq : OCGN managementOcugen, Inc. Announces Connie Collingsworth Joins Business Advisory BoardOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Connie Collingsworth, former ChiefRHEA-AIneutral
09/20/23 8:00 AMNasdaq : OCGN conferencesOcugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, ChiefRHEA-AIneutral
09/13/23 8:15 AMNasdaq : OCGN clinical trialOcugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to date Clinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-LuminanceRHEA-AIpositive
09/12/23 7:30 PMNasdaq : OCGN conferencesOcugen to Host Virtual Investor & Analyst Event on September 13, 2023Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,RHEA-AIneutral
08/21/23 4:32 PMNasdaq : OCGN earningsOcugen Provides Business Update with Second Quarter 2023 Financial ResultsConference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease • OCU400 Clinical Study Results Update Expected This Quarter MALVERN, Pa., Aug. 21, 2023 (GLOBERHEA-AIneutral
08/18/23 4:39 PMNasdaq : OCGN conferencesearningsOcugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial ResultsOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and liveRHEA-AIneutral
06/30/23 8:00 AMNasdaq : OCGN conferencesOcugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific AssemblyOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chairman, CEO andRHEA-AIneutral
06/09/23 4:05 PMNasdaq : OCGN Ocugen, Inc. Announces Adjournment of Annual Meeting of ShareholdersOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s 2023 Annual Meeting ofRHEA-AIneutral